Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression ...Middle East

TORONTO, June 2, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and psilocybin treatments for depression and related mental...

Read More Details
Finally We wish PressBee provided you with enough information of ( Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression )

Also on site :

• NYT Mini Crossword Answers, Hints for Friday, June 20, 2025
• Country 'MVP' Refunds Entire Audience Mid-Concert and Fans 'Cannot Believe He Did That'
• Legendary '70s Rock Band’s Song Sparks Fan Theories 50 Years Later